Long-Term Safety and Survival Outcomes of 225AcAc-PSMA (Prostate-Specific Membrane Antigen) and 225AcAc-/177LuLu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer | Synapse
January 26, 2025Open Access
Long-Term Safety and Survival Outcomes of 225AcAc-PSMA (Prostate-Specific Membrane Antigen) and 225AcAc-/177LuLu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Lu]Lu-PSMA as TANDEM PRLT, is generally safe in terms of both tolerance after the radiopharmaceutical administration and long-term toxicity.